Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Pipeline

DelveInsight’s, “Acute Bacterial Skin and Skin Structure Infections (ABSSSI)- Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Understanding

Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Overview

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) refer to a group of bacterial infections affecting the skin and its underlying tissues. These infections are typically characterized by rapid onset and may involve lesions that are at least 75 cm² in surface area. Common clinical entities under ABSSSI include cellulitis, erysipelas, wound infections, and major cutaneous abscesses. These infections are often caused by Gram-positive pathogens, particularly Staphylococcus aureus (including MRSA) and Streptococcus pyogenes. ABSSSIs are considered a significant burden on healthcare systems due to their high incidence, potential for complications, and frequent need for hospitalization.

Signs and symptoms of ABSSSI vary depending on the type and severity of the infection but generally include localized redness (erythema), swelling, warmth, and pain at the affected site. Fever and systemic signs such as chills, fatigue, or elevated white blood cell count may occur in more severe cases. In abscesses, purulent drainage is commonly observed. Cellulitis may cause diffuse inflammation, while erysipelas presents with sharply demarcated edges. In wound infections, signs of delayed healing or spreading erythema are typically present. Causes of ABSSSI are predominantly bacterial, with S. aureus (including methicillin-resistant strains) and β-hemolytic streptococci being the most common pathogens. Risk factors include skin trauma (cuts, insect bites, or surgery), underlying skin conditions (eczema, psoriasis), diabetes, obesity, immunosuppression, and poor hygiene. In healthcare settings, surgical sites and catheter insertions are potential entry points for bacteria.

Diagnosis involves clinical evaluation based on the patient’s history and physical examination. Laboratory tests such as complete blood count (CBC), C-reactive protein (CRP), and bacterial cultures (from pus or tissue swabs) can help confirm the infection and identify the causative organism. Imaging (ultrasound, CT, or MRI) may be used in deeper or complex infections to assess the extent of tissue involvement or detect abscesses.

Treatment of ABSSSI depends on the severity and suspected pathogen. Mild cases may be managed with oral antibiotics such as cephalexin or clindamycin, while moderate to severe cases—especially those caused by MRSA—often require intravenous agents like vancomycin, linezolid, or daptomycin. Surgical drainage is essential in abscesses. Proper wound care, hygiene, and management of underlying conditions are crucial to prevent recurrence. With timely and appropriate treatment, most ABSSSI cases resolve without long-term complications.

 

"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) pipeline landscape is provided which includes the disease overview and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) treatment guidelines. The assessment part of the report embraces, in depth Acute Bacterial Skin and Skin Structure Infections (ABSSSI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Bacterial Skin and Skin Structure Infections (ABSSSI) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Bacterial Skin and Skin Structure Infections (ABSSSI) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

 

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emerging Drugs Chapters

This segment of the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emerging Drugs

• TNP-2092: TenNor Therapeutics

TNP-2092 is a multi-targeting conjugated drug that delivers potent bactericidal activities against biofilms through a multi-targeting synergistic mechanism of action by inhibiting RNA polymerase, DNA gyrase, and DNA topoisomerase IV, significantly reduces the frequency of resistance. It has a broad application in the treatment of biofilm infections associated with implanted medical devices. So far five Phase I and II clinical trials have been completed in the United States, demonstrating good safety and efficacy in the patients with acute bacterial skin and skin structure infections. Currently, the drug is in the Phase II stage of its development for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The drug is currently being investigated in the Phase II stage of development for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Further product details are provided in the report……..

 

Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Therapeutic Assessment

This segment of the report provides insights about the different Acute Bacterial Skin and Skin Structure Infections (ABSSSI) drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

There are approx. 2+ key companies which are developing the therapies for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The companies which have their Acute Bacterial Skin and Skin Structure Infections (ABSSSI) drug candidates in the most advanced stage, i.e. Phase II include, TenNor Therapeutics.

 

Phases

DelveInsight’s report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Bacterial Skin and Skin Structure Infections (ABSSSI) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Bacterial Skin and Skin Structure Infections (ABSSSI) drugs.

 

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Report Insights

• Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Bacterial Skin and Skin Structure Infections (ABSSSI) drugs?
• How many Acute Bacterial Skin and Skin Structure Infections (ABSSSI) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and their status?
• What are the key designations that have been granted to the emerging drugs?